Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
The global market for Biologics and Biosimilars was estimated to be worth US$ 468270 million in 2023 and is forecast to a readjusted size of US$ 674510 million by 2030 with a CAGR of 8.7% during the forecast period 2024-2030.
Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the largest manufacturer being Pfizer with over 20% share. In terms of product categories, monoclonal antibodies are the largest segment with a market share of 43%, followed by vaccines with a 30% share. In terms of applications, hospitals are the top application area, with about 85% of the market share.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biologics and Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Biologics and Biosimilars.
The Biologics and Biosimilars market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biologics and Biosimilars market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biologics and Biosimilars companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
麻豆原创 Segmentation
By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
Segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Biologics and Biosimilars in global and regional level.
Chapter 3: Detailed analysis of Biologics and Biosimilars company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biologics and Biosimilars revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 Biologics and Biosimilars Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global Biologics and Biosimilars 麻豆原创 Size Growth Rate by Type (2019 VS 2023 VS 2030)
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Insulin
1.2.5 Vaccines
1.2.6 Others
1.3 麻豆原创 by Application
1.3.1 Global Biologics and Biosimilars 麻豆原创 Size Growth Rate by Application (2019 VS 2023 VS 2030)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Biologics and Biosimilars 麻豆原创 Size Estimates and Forecasts
2.2 Biologics and Biosimilars 麻豆原创 Size by Region: 2023 Versus 2030
2.2.1 Global Biologics and Biosimilars Revenue by Region: 2019-2024
2.2.2 Global Biologics and Biosimilars Revenue Forecast by Region (2025-2030)
2.2.3 Global Biologics and Biosimilars Revenue 麻豆原创 Share by Region (2019-2030)
3 Global Biologics and Biosimilars by Company
3.1 Global Biologics and Biosimilars Revenue by Company (2019-2024)
3.2 Global Biologics and Biosimilars Revenue Share by Company (2019-2024)
3.3 Competitive Landscape
3.3.1 Key Biologics and Biosimilars Companies around the World: Ranking by Revenue
3.3.2 Global Biologics and Biosimilars 麻豆原创 Concentration Ratio (CR5 and HHI) & (2019-2024)
3.3.3 Global Biologics and Biosimilars 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.4 Global Biologics and Biosimilars Companies Headquarters & Product Type
3.4.1 Biologics and Biosimilars Companies Headquarters
3.4.2 Global Biologics and Biosimilars Companies Product & Service
3.4.3 Date of International Companies Enter into Biologics and Biosimilars 麻豆原创
3.5 Global Biologics and Biosimilars Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Roche
4.1.1 Roche Company Information
4.1.2 Roche Description, Business Overview
4.1.3 Roche Biologics and Biosimilars Products Offered
4.1.4 Roche Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.1.5 Roche Biologics and Biosimilars Revenue by Product in 2023
4.1.6 Roche Biologics and Biosimilars Revenue by Application in 2023
4.1.7 Roche Biologics and Biosimilars Revenue by Geographic Area in 2023
4.1.8 Roche Recent Developments
4.2 Amgen
4.2.1 Amgen Company Information
4.2.2 Amgen Description, Business Overview
4.2.3 Amgen Biologics and Biosimilars Products Offered
4.2.4 Amgen Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.2.5 Amgen Biologics and Biosimilars Revenue by Product in 2023
4.2.6 Amgen Biologics and Biosimilars Revenue by Application in 2023
4.2.7 Amgen Biologics and Biosimilars Revenue by Geographic Area in 2023
4.2.8 Amgen Recent Developments
4.3 AbbVie
4.3.1 AbbVie Company Information
4.3.2 AbbVie Description, Business Overview
4.3.3 AbbVie Biologics and Biosimilars Products Offered
4.3.4 AbbVie Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.3.5 AbbVie Biologics and Biosimilars Revenue by Product in 2023
4.3.6 AbbVie Biologics and Biosimilars Revenue by Application in 2023
4.3.7 AbbVie Biologics and Biosimilars Revenue by Geographic Area in 2023
4.3.8 AbbVie Recent Developments
4.4 Sanofi
4.4.1 Sanofi Company Information
4.4.2 Sanofi Description, Business Overview
4.4.3 Sanofi Biologics and Biosimilars Products Offered
4.4.4 Sanofi Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.4.5 Sanofi Biologics and Biosimilars Revenue by Product in 2023
4.4.6 Sanofi Biologics and Biosimilars Revenue by Application in 2023
4.4.7 Sanofi Biologics and Biosimilars Revenue by Geographic Area in 2023
4.4.8 Sanofi Recent Developments
4.5 Johnson & Johnson
4.5.1 Johnson & Johnson Company Information
4.5.2 Johnson & Johnson Description, Business Overview
4.5.3 Johnson & Johnson Biologics and Biosimilars Products Offered
4.5.4 Johnson & Johnson Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.5.5 Johnson & Johnson Biologics and Biosimilars Revenue by Product in 2023
4.5.6 Johnson & Johnson Biologics and Biosimilars Revenue by Application in 2023
4.5.7 Johnson & Johnson Biologics and Biosimilars Revenue by Geographic Area in 2023
4.5.8 Johnson & Johnson Recent Developments
4.6 Pfizer
4.6.1 Pfizer Company Information
4.6.2 Pfizer Description, Business Overview
4.6.3 Pfizer Biologics and Biosimilars Products Offered
4.6.4 Pfizer Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.6.5 Pfizer Biologics and Biosimilars Revenue by Product in 2023
4.6.6 Pfizer Biologics and Biosimilars Revenue by Application in 2023
4.6.7 Pfizer Biologics and Biosimilars Revenue by Geographic Area in 2023
4.6.8 Pfizer Recent Development
4.7 Novo Nordisk
4.7.1 Novo Nordisk Company Information
4.7.2 Novo Nordisk Description, Business Overview
4.7.3 Novo Nordisk Biologics and Biosimilars Products Offered
4.7.4 Novo Nordisk Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.7.5 Novo Nordisk Biologics and Biosimilars Revenue by Product in 2023
4.7.6 Novo Nordisk Biologics and Biosimilars Revenue by Application in 2023
4.7.7 Novo Nordisk Biologics and Biosimilars Revenue by Geographic Area in 2023
4.7.8 Novo Nordisk Recent Development
4.8 Eli Lilly
4.8.1 Eli Lilly Company Information
4.8.2 Eli Lilly Description, Business Overview
4.8.3 Eli Lilly Biologics and Biosimilars Products Offered
4.8.4 Eli Lilly Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.8.5 Eli Lilly Biologics and Biosimilars Revenue by Product in 2023
4.8.6 Eli Lilly Biologics and Biosimilars Revenue by Application in 2023
4.8.7 Eli Lilly Biologics and Biosimilars Revenue by Geographic Area in 2023
4.8.8 Eli Lilly Recent Development
4.9 Novartis
4.9.1 Novartis Company Information
4.9.2 Novartis Description, Business Overview
4.9.3 Novartis Biologics and Biosimilars Products Offered
4.9.4 Novartis Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.9.5 Novartis Biologics and Biosimilars Revenue by Product in 2023
4.9.6 Novartis Biologics and Biosimilars Revenue by Application in 2023
4.9.7 Novartis Biologics and Biosimilars Revenue by Geographic Area in 2023
4.9.8 Novartis Recent Development
4.10 Merck
4.10.1 Merck Company Information
4.10.2 Merck Description, Business Overview
4.10.3 Merck Biologics and Biosimilars Products Offered
4.10.4 Merck Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.10.5 Merck Biologics and Biosimilars Revenue by Product in 2023
4.10.6 Merck Biologics and Biosimilars Revenue by Application in 2023
4.10.7 Merck Biologics and Biosimilars Revenue by Geographic Area in 2023
4.10.8 Merck Recent Development
4.11 Biogen
4.11.1 Biogen Company Information
4.11.2 Biogen Description, Business Overview
4.11.3 Biogen Biologics and Biosimilars Products Offered
4.11.4 Biogen Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.11.5 Biogen Biologics and Biosimilars Revenue by Product in 2023
4.11.6 Biogen Biologics and Biosimilars Revenue by Application in 2023
4.11.7 Biogen Biologics and Biosimilars Revenue by Geographic Area in 2023
4.11.8 Biogen Recent Development
4.12 Celltrion
4.12.1 Celltrion Company Information
4.12.2 Celltrion Description, Business Overview
4.12.3 Celltrion Biologics and Biosimilars Products Offered
4.12.4 Celltrion Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.12.5 Celltrion Biologics and Biosimilars Revenue by Product in 2023
4.12.6 Celltrion Biologics and Biosimilars Revenue by Application in 2023
4.12.7 Celltrion Biologics and Biosimilars Revenue by Geographic Area in 2023
4.12.8 Celltrion Recent Development
4.13 Sobi
4.13.1 Sobi Company Information
4.13.2 Sobi Description, Business Overview
4.13.3 Sobi Biologics and Biosimilars Products Offered
4.13.4 Sobi Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.13.5 Sobi Biologics and Biosimilars Revenue by Product in 2023
4.13.6 Sobi Biologics and Biosimilars Revenue by Application in 2023
4.13.7 Sobi Biologics and Biosimilars Revenue by Geographic Area in 2023
4.13.8 Sobi Recent Development
4.14 3SBIO
4.14.1 3SBIO Company Information
4.14.2 3SBIO Description, Business Overview
4.14.3 3SBIO Biologics and Biosimilars Products Offered
4.14.4 3SBIO Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.14.5 3SBIO Biologics and Biosimilars Revenue by Product in 2023
4.14.6 3SBIO Biologics and Biosimilars Revenue by Application in 2023
4.14.7 3SBIO Biologics and Biosimilars Revenue by Geographic Area in 2023
4.14.8 3SBIO Recent Development
4.15 Changchun High Tech
4.15.1 Changchun High Tech Company Information
4.15.2 Changchun High Tech Description, Business Overview
4.15.3 Changchun High Tech Biologics and Biosimilars Products Offered
4.15.4 Changchun High Tech Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.15.5 Changchun High Tech Biologics and Biosimilars Revenue by Product in 2023
4.15.6 Changchun High Tech Biologics and Biosimilars Revenue by Application in 2023
4.15.7 Changchun High Tech Biologics and Biosimilars Revenue by Geographic Area in 2023
4.15.8 Changchun High Tech Recent Development
4.16 Kanghong Pharma
4.16.1 Kanghong Pharma Company Information
4.16.2 Kanghong Pharma Description, Business Overview
4.16.3 Kanghong Pharma Biologics and Biosimilars Products Offered
4.16.4 Kanghong Pharma Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.16.5 Kanghong Pharma Biologics and Biosimilars Revenue by Product in 2023
4.16.6 Kanghong Pharma Biologics and Biosimilars Revenue by Application in 2023
4.16.7 Kanghong Pharma Biologics and Biosimilars Revenue by Geographic Area in 2023
4.16.8 Kanghong Pharma Recent Development
4.17 Innovent Biologics
4.17.1 Innovent Biologics Company Information
4.17.2 Innovent Biologics Description, Business Overview
4.17.3 Innovent Biologics Biologics and Biosimilars Products Offered
4.17.4 Innovent Biologics Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.17.5 Innovent Biologics Biologics and Biosimilars Revenue by Product in 2023
4.17.6 Innovent Biologics Biologics and Biosimilars Revenue by Application in 2023
4.17.7 Innovent Biologics Biologics and Biosimilars Revenue by Geographic Area in 2023
4.17.8 Innovent Biologics Recent Development
4.18 Gan&Lee
4.18.1 Gan&Lee Company Information
4.18.2 Gan&Lee Description, Business Overview
4.18.3 Gan&Lee Biologics and Biosimilars Products Offered
4.18.4 Gan&Lee Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.18.5 Gan&Lee Biologics and Biosimilars Revenue by Product in 2023
4.18.6 Gan&Lee Biologics and Biosimilars Revenue by Application in 2023
4.18.7 Gan&Lee Biologics and Biosimilars Revenue by Geographic Area in 2023
4.18.8 Gan&Lee Recent Development
4.19 Tonghua Dongbao
4.19.1 Tonghua Dongbao Company Information
4.19.2 Tonghua Dongbao Description, Business Overview
4.19.3 Tonghua Dongbao Biologics and Biosimilars Products Offered
4.19.4 Tonghua Dongbao Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.19.5 Tonghua Dongbao Biologics and Biosimilars Revenue by Product in 2023
4.19.6 Tonghua Dongbao Biologics and Biosimilars Revenue by Application in 2023
4.19.7 Tonghua Dongbao Biologics and Biosimilars Revenue by Geographic Area in 2023
4.19.8 Tonghua Dongbao Recent Development
4.20 United Laboratory
4.20.1 United Laboratory Company Information
4.20.2 United Laboratory Description, Business Overview
4.20.3 United Laboratory Biologics and Biosimilars Products Offered
4.20.4 United Laboratory Biologics and Biosimilars Revenue and Gross Margin (2019-2024)
4.20.5 United Laboratory Biologics and Biosimilars Revenue by Product in 2023
4.20.6 United Laboratory Biologics and Biosimilars Revenue by Application in 2023
4.20.7 United Laboratory Biologics and Biosimilars Revenue by Geographic Area in 2023
4.20.8 United Laboratory Recent Development
5 Breakdown Data by Type
5.1 Global Biologics and Biosimilars Revenue by Type (2019-2024)
5.2 Global Biologics and Biosimilars Revenue Forecast by Type (2025-2030)
5.3 Biologics and Biosimilars Revenue 麻豆原创 Share by Type (2019-2030)
6 Breakdown Data by Application
6.1 Global Biologics and Biosimilars Revenue by Application (2019-2024)
6.2 Global Biologics and Biosimilars Revenue Forecast by Application (2025-2030)
6.3 Biologics and Biosimilars Revenue 麻豆原创 Share by Application (2019-2030)
7 North America
7.1 North America Biologics and Biosimilars 麻豆原创 Size YoY Growth 2019-2030
7.2 North America Biologics and Biosimilars 麻豆原创 Facts & Figures by Country (2019-2030)
7.3 North America Biologics and Biosimilars Revenue by Type (2019-2024)
7.4 North America Biologics and Biosimilars Revenue by Application (2019-2024)
8 Asia-Pacific
8.1 Asia-Pacific Biologics and Biosimilars 麻豆原创 Size YoY Growth 2019-2030
8.2 Asia-Pacific Biologics and Biosimilars 麻豆原创 Facts & Figures by Region (2019-2030)
8.3 Asia-Pacific Biologics and Biosimilars Revenue by Type (2019-2024)
8.4 Asia-Pacific Biologics and Biosimilars Revenue by Application (2019-2024)
9 Europe
9.1 Europe Biologics and Biosimilars 麻豆原创 Size YoY Growth 2019-2030
9.2 Europe Biologics and Biosimilars 麻豆原创 Facts & Figures by Country (2019-2030)
9.3 Europe Biologics and Biosimilars Revenue by Type (2019-2024)
9.4 Europe Biologics and Biosimilars Revenue by Application (2019-2024)
10 Latin America
10.1 Latin America Biologics and Biosimilars 麻豆原创 Size YoY Growth 2019-2030
10.2 Latin America Biologics and Biosimilars 麻豆原创 Facts & Figures by Country (2019-2030)
10.3 Latin America Biologics and Biosimilars Revenue by Type (2019-2024)
10.4 Latin America Biologics and Biosimilars Revenue by Application (2019-2024)
11 Middle East and Africa
11.1 Middle East and Africa Biologics and Biosimilars 麻豆原创 Size YoY Growth 2019-2030
11.2 Middle East and Africa Biologics and Biosimilars 麻豆原创 Facts & Figures by Country (2019-2030)
11.3 Middle East and Africa Biologics and Biosimilars Revenue by Type (2019-2024)
11.4 Middle East and Africa Biologics and Biosimilars Revenue by Application (2019-2024)
12 Supply Chain and Sales Channel Analysis
12.1 Biologics and Biosimilars Supply Chain Analysis
12.2 Biologics and Biosimilars Key Raw Materials and Upstream Suppliers
12.3 Biologics and Biosimilars Clients Analysis
12.4 Biologics and Biosimilars Sales Channel and Sales Model Analysis
12.4.1 Biologics and Biosimilars Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Biologics and Biosimilars Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Biologics and Biosimilars Distributors
13 麻豆原创 Dynamics
13.1 Biologics and Biosimilars Industry Trends
13.2 Biologics and Biosimilars 麻豆原创 Drivers
13.3 Biologics and Biosimilars 麻豆原创 Challenges
13.4 Biologics and Biosimilars 麻豆原创 Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
听
听
*If Applicable.